A Phase 1/2 interventional study of Arginine and Arginine (Loading) in Sickle Cell Disease, sponsored by Emory University. Recruiting at 2 sites in United States. Open to participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Emory University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.
Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2015, is the only one in phase 1/2, and was the 12th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 8–18
Emory University · Sites in United States
Ages 7–18
Emory University · Sites in United States
Ages 12–18
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 7 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 24 across the 25 interventional studies, 20 across the 4 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
4 of the studies in Anemia, Sickle Cell by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT07090668Emory UniversityTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease | 2027-01 |
| NCT03924401Emory UniversityAcute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant | 2027-03-01 |
| NCT06691867Emory UniversityIntegrative Training Program for Pediatric Sickle Cell Pain | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 29 studies in Anemia, Sickle Cell by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Arginine is a simple amino acid that is found in many foods and is part of the proteins in a human's body. Patients with sickle cell disease have low levels of the amino acid arginine and these low levels may be related to pain episodes. Increasing levels of arginine in the blood may lower pain and/or lower the amount of pain medication (like morphine) that is needed to treated them. It may also decrease the amount of time spent in the hospital.
Available data suggest that, L-arginine is a safe \& efficacious intervention with narcotic-sparing effects in pediatric SCD patients with VOE. The addition of a higher loading dose to the standard dose or use of a continuous infusion may provide additional clinical benefits by overcoming multiple mechanisms that limit global arginine bioavailability in SCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
Drug: Arginine
Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
Drug: Arginine · Drug: Arginine (Loading)
Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
Drug: Arginine (Loading) · Drug: Arginine (Continuous)
Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 500 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Drug: Arginine (Loading)
Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 300 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Drug: Arginine (Loading)
Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 400 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Drug: Arginine (Loading)
Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge. * Loading dose: 200 mg/kg once * Continuous IV: 300 mg/kg/24 hours
Also known as: Arginine Hydrochloride Injection, R-Gene® 10
Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Also known as: Arginine Hydrochloride Injection, R-Gene® 10
Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Also known as: Arginine Hydrochloride Injection, R-Gene® 10
Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time
Total time plasma arginine levels are maintained above the half-saturating concentration (Km) of cationic amino acid transporter protein-1 (CAT-1), which is 150 µM (normal range of extracellular plasma arginine concentration). pK samples will be collected at 6 time-points within 8 hours: prior to arginine treatment (time 0), and at 60, 90, 120 minutes, 4 and 8 hours after the initiation of arginine therapy, and then every 24 hours up to 7 days.
Time frame: Day 1 through study completion, an average of up to 7 days
Change in nitric oxide metabolites
The formation of NO metabolites will be measured by determination of its stable end products in serum; nitrite (NO2-) and nitrate (NO3-). Change in nitric oxide metabolites will be calculated as the difference in metabolites from the time prior to arginine treatment (baseline) to the end of the intervention period.
Time frame: Baseline, day 1 through study completion, an average of up to 7 days
Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine
AUC is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\])
Time frame: Day 1
Maximum observed plasma concentration of arginine
Maximum measured concentration of the arginine in plasma
Time frame: Day 1
Apparent clearance of arginine
The clearance of a drug measures the rate at which the drug is removed from the body after the dose. Clearance of arginine after intravenous administration on day 1.
Time frame: Day 1
Terminal elimination half-life (t1/2) for arginine
Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Day 1
Change in red blood cell (RBC) arginine
Change in rbc arginine will be calculated as rbc arginine at the end of arginine administration minus rbc arginine at baseline.
Time frame: Baseline, day 1 through study completion, an average of up to 7 days
Daily urine arginine
Total amount of arginine excreted in urine daily
Time frame: From Day 1 until study completion, an average of up to 7 days
Global arginine bioavailability (GABR)
GABR represents a measure of endothelial function. GABR will be calculated by arginine divided by the sum of ornithine plus citrulline \[arginine/(ornithine+citrulline)\].
Time frame: From enrollment through study completion, an average of up to 7 days
Change in asymmetric dimethylarginine (ADMA) levels
ADMA is is a metabolic by-product of continual protein modification processes and interferes with L-arginine in the production of nitric oxide. Change in ADMA levels will be calculated as ADMA levels at the end of arginine administration minus ADMA levels at baseline.
Time frame: Baseline, day 1 and through study completion, an average of up to 7 days
Modeling nitric oxide (NOx) level versus plasma arginine level
Modeling nitric oxide (NOx) level versus plasma arginine level will be measured.
Time frame: From enrollment through study completion, an average of up to 7 days
Biomarkers of hemolysis
Biomarkers of hemolysis (lactate dehydrogenase, hemoglobin, reticulocytes, arginase, indirect bilirubin) represent intravascular hemolysis and nitric oxide bioavailability.
Time frame: From enrollment through study completion, an average of up to 7 days
Erythrocyte glutathione levels
Erythrocyte glutathione is a biomarker for oxidative stress. It will be measured by using liquid chromatography.
Time frame: From enrollment through study completion, an average of up to 7 days
Level of cytokines
Cytokines are biomarkers for inflammation. Cell supernatants will be collected and analyzed for different cytokines.
Time frame: From enrollment through study completion, an average of up to 7 days
The record gives a start of May 2015, a primary completion of Jan 2028 and a completion of Jan 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine